Anabaseine Derivatives Selective Alpha7 Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Alzheimer's and schizophrenia lack selective α7 nicotinic receptor agonists that do not interfere with other nicotinic receptor subtypes, leading to unwanted side effects.
Innovation Solution
Development of novel anabaseine-based compounds with a chiral bicyclic tetrahydropyridyl ring scaffold that selectively bind and activate α7 nicotinic receptors, minimizing interaction with α4β2 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If arylidene-anabaseines are used to activate α7 nicotinic receptors, then cognitive enhancement is achieved, but unwanted side effects occur due to binding with other nicotinic receptor subtypes
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (bicyclic tetrahydropyridyl ring scaffold with particular stereochemistry) that create selective interaction with α7 nicotinic receptors. The molecular structure is optimized to match the specific binding pocket characteristics of α7 receptors, enabling selective activation while avoiding other nicotinic receptor subtypes.
Solution Approach 2:
The invention utilizes asymmetry through the chiral bicyclic tetrahydropyridyl ring structure. The specific stereochemical configuration (R or S enantiomers) creates an asymmetric molecular shape that selectively fits the α7 receptor binding site, providing high selectivity and avoiding cross-reactivity with other nicotinic receptor subtypes that have different binding pocket geometries.
2Adaptability or versatility
If non-selective nicotinic receptor agonists are used, then multiple nicotinic receptor subtypes are activated, but selectivity for α7 receptors is lost
Solution Approach 1:
The compounds feature a bicyclic tetrahydropyridyl ring scaffold with specific substituents positioned to create local interactions with key residues in the α7 receptor binding pocket. This localized structural optimization provides high selectivity for α7 receptors while maintaining agonist activity, distinguishing it from other nicotinic receptor subtypes.
Solution Approach 2:
The invention changes molecular parameters including ring size, stereochemistry, and substituent positioning to optimize selectivity. The bicyclic structure with specific ring junction stereochemistry and aromatic substituent orientation creates a unique molecular profile that selectively engages α7 receptors, transforming the compound's receptor interaction profile from non-selective to highly selective.
Data Source
AI summary
The invention relates to the design and synthesis of novel anabaseine-based compounds, which are useful in treating or preventing a wide variety of conditions, including nervous system diseases or disorders, such as, schizophrenia, Alzheimer's disease, Parkinson's disease, drug dependence, and substance addiction, and compositions, kits, and methods thereof. The invention also provides novel anabaseine-based compounds, compositions, kits, and methods thereof for treating or preventing non-nerve system diseases or disorders (such as, inflammation and cancer) in a subject identified in need thereof. Certain enantiomeric compounds of the invention exhibited enhanced selectivity toward alpha7 nAChRs relative to alpha4beta2 nAChRs. Other enantiomeric compounds of the invention exhibited enhanced selectivity for alpha4beta2 nAChRs relative to alpha7 nAChRs.